Viatris (VTRS) came out with quarterly earnings of $0.57 per share, beating the Zacks Consensus Estimate of $0.52 per share. This compares to earnings of $0.54 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +9.62%. A quarter ago, it was expected that this generic drugmaker would post earnings of $0.63 per share when it actually produced earnings of $0.67, delivering a surprise of +6.35%.Over the last four quarters, the compan ...

Ademi LLP Investigates Claims of Securities Fraud against Driven Brands Holdings Inc. [Accessibility Statement] Skip NavigationMILWAUKEE, Feb. 25, 2026 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against Driven Brands (NASDAQ: DRVN). The investigation results from inaccurate statements Driven Brands may have made regarding its financial statements, business operations and prospects.Click [here] to join our investigation or to obtain additional information, or contact us at [[ ...

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Thermon Group Holdings, Inc. (NYSE: THR) [Accessibility Statement] Skip NavigationNEW YORK, Feb. 24, 2026 /PRNewswire/ -- Class Action Attorney [Juan Monteverde] with [Monteverde & Associates PC](the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York C ...

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of CECO Environmental Corp. (NASDAQ: CECO) [Accessibility Statement] Skip NavigationNEW YORK, Feb. 24, 2026 /PRNewswire/ -- Class Action Attorney [Juan Monteverde] with [Monteverde & Associates PC](the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York Ci ...

U.S. stocks were lower, with the Dow Jones index falling around 400 points on Monday.Shares of ImmunityBio, Inc. (NASDAQ:IBRX) rose sharply on Monday after the company reported better-than-expected quarterly financial results.ImmunityBio reported quarterly losses of 6 cents per share which beat the analyst consensus estimate of losses of 9 cents per share. The company reported quarterly sales of $38.285 million which beat the analyst consensus estimate of $37.020 million.ImmunityBio shares jumped 22.2% to $ ...

Core Insights - UnitedHealth Group Incorporated (UNH) reported fourth-quarter 2025 adjusted earnings per share (EPS) of $2.11, exceeding the Zacks Consensus Estimate of $2.09, but reflecting a 69% decline year over year [1] - Revenues increased by 12% year over year to $113.2 billion, slightly missing the consensus mark [1] Financial Performance - The quarterly earnings were supported by growth in commercial fee-based membership and strong performance in Optum Rx, although elevated medical costs and a decline in risk-based membership partially offset these positives [2] - For the full year 2025, revenues rose nearly 12% year over year to $447.6 billion, but also marginally missed the consensus estimate [3] - UnitedHealth's fourth-quarter premium reached $88.8 billion, up from $76.5 billion a year ago, but fell short of the consensus estimate of $89 billion [4] Medical Care and Operating Costs - The adjusted medical care ratio (MCR) for the fourth quarter was 91.5%, worsening by 640 basis points from the previous year and below the Zacks Consensus Estimate of 92.2% [5] - Total operating costs for the fourth quarter were $112.8 billion, a 21.3% increase year over year, exceeding the model estimate of $109.4 billion [6] Business Segments - Revenues from UnitedHealthcare, the health benefits segment, grew 17.5% year over year to $87.1 billion, but missed the Zacks Consensus Estimate of $87.3 billion [7] - Optum's revenues were $70.3 billion, up from $65.1 billion a year ago, surpassing the consensus mark of $67.6 billion [9] Financial Position - As of December 31, 2025, UnitedHealth had cash and short-term investments of $28.1 billion, down from $29.1 billion at the end of 2024 [12] - Total equity increased to $100.1 billion from $98.3 billion at the end of 2024 [13] 2026 Outlook - Management projects revenues for 2026 to exceed $439 billion, which is below the 2025 level, with adjusted EPS expected to be at least $17.75, indicating improving margins [14] - The company anticipates MCR to be around 88.8% in 2026, down from 89.1% in 2025, and expects operating cash flows to be $18 billion, a decrease from 2025 [15]

Company Performance - Progyny (PGNY) has seen a stock increase of 5.5% over the past month, reaching a new 52-week high of $28.49 [1] - Year-to-date, Progyny's stock has gained 6.8%, compared to 7.8% for the Zacks Medical sector and 10.9% for the Zacks Medical Services industry [1] Earnings and Revenue - Progyny has consistently beaten earnings estimates, with a reported EPS of $0.45 against a consensus estimate of $0.39 in its last earnings report [2] - For the current fiscal year, Progyny is expected to post earnings of $1.93 per share on revenues of $1.27 billion, with a year-over-year change of 7.22% [3] - For the next fiscal year, earnings are projected to be $2.11 per share on revenues of $1.39 billion, reflecting a year-over-year change of 9.24% [3] Valuation Metrics - Progyny's current valuation metrics show a trading multiple of 14.2X current fiscal year EPS estimates, below the peer industry average of 15.3X [7] - The stock trades at a trailing cash flow basis of 79.5X compared to the peer group's average of 11.2X, and has a PEG ratio of 0.85 [7] Zacks Rank and Style Scores - Progyny holds a Zacks Rank of 2 (Buy) due to a solid earnings estimate revision trend [8] - The company has a Value Score of B, a Growth Score of A, and a Momentum Score of C, resulting in a combined VGM Score of A [6][8] Industry Comparison - In comparison to peers, Enhabit, Inc. (EHAB) also shows strong performance with a Zacks Rank of 2 (Buy) and a Value Score of A [9] - Enhabit, Inc. reported earnings that beat consensus estimates by 41.67%, with expected earnings of $0.53 per share on revenue of $1.06 billion for the current fiscal year [10]

Core Insights - Aveanna Healthcare (AVAH) is set to report its third-quarter 2025 results on November 6, with previous earnings per share (EPS) of 18 cents exceeding estimates by 350% [1] Preliminary Q3 Results - Preliminary results indicate revenues between $616 million and $624 million, reflecting a year-over-year growth of 21.0% to 22.6%, driven by improved reimbursement rates and increased care-hour delivery [2] - Estimated net income ranges from $11 million to $15 million, showing a growth of approximately 126% to 135% year-over-year, while adjusted EBITDA is projected between $77 million and $81 million, indicating a year-over-year increase of about 61% to 69% [3] Factors Influencing Performance - Continued improvements in reimbursement rates and expansion of preferred-payer relationships likely supported revenue quality and performance in Q3 [4] - The expansion of preferred payers is expected to enhance pricing mix and stabilize revenue per hour, particularly in Private Duty Services [5] - Improvements in caregiver recruitment and retention have likely converted strong demand into more care hours delivered, contributing to revenue growth [6] Margin and Cash Generation - Incremental operating leverage and solid margin performance earlier in the year are expected to benefit Q3 earnings, with adjusted EBITDA reaching $88.4 million at a 15% margin in Q2 [7] - A year-to-date free cash flow of approximately $36.9 million positions the company well for continued cash generation in Q3 [9] Earnings Estimates - The Zacks Consensus Estimate for Q3 EPS is set at 8 cents, implying a 300% improvement from the prior-year quarter [10] Share Price Performance - Year-to-date, AVAH shares have increased by 105.9%, outperforming the Medical Outpatient and Home Healthcare Market's growth of 5.1% and the S&P 500 Composite's increase of 18% [13][14] Long-Term Investment Outlook - Management has raised full-year guidance to over $2.3 billion in revenues and more than $270 million in adjusted EBITDA, indicating confidence in sustained growth from improved reimbursement trends and operational efficiencies [17] - The company’s diverse service segments, including Private Duty Services and Home Health & Hospice, support a favorable long-term growth setup [18] - An improving cash-generation profile enhances the company's ability to reinvest in markets and pursue acquisitions, positioning it well for future revenue and earnings growth [19]

Company Overview - Progyny (PGNY) shares increased by 13.2% to $24.27 in the last trading session, with a higher-than-average trading volume, contrasting with a 2.4% loss over the past four weeks [1] - The company is a provider of fertility and family building benefits [2] Financial Performance Expectations - Progyny anticipates its Q2 2025 financial results (revenues, adjusted net income, and adjusted EBITDA) to exceed the guidance provided during the Q1 earnings call [2] - The expected quarterly earnings per share (EPS) is $0.42, reflecting a year-over-year decline of 2.3%, while revenues are projected to be $314.93 million, an increase of 3.6% from the previous year [3] Earnings Estimate Trends - The consensus EPS estimate for Progyny has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4] - The stock currently holds a Zacks Rank of 3 (Hold), suggesting a neutral outlook [4] Industry Context - Progyny is part of the Zacks Medical Services industry, which includes other companies like Enhabit (EHAB), which experienced a 0.3% decline in the last trading session and has returned -32.1% over the past month [4] - Enhabit has a consensus EPS estimate of $0.1 for its upcoming report, representing a 42.9% increase from the previous year, and also holds a Zacks Rank of 3 (Hold) [5]

Core Business Performance - Danaher Corporation (DHR) is experiencing strong momentum in its clinical diagnostics business, particularly from the Leica Biosystems and Beckman Colter Diagnostics units, with positive responses to new products like Aperio GT 450 DX and Access NT ProBNP, both of which received FDA 510K clearance [1] - The Diagnostics segment's core revenues increased by 3% year over year in 2024, with expectations for 2025 to remain flat or increase in low-single-digits [2] - The acquisition of Abcam plc for approximately $5.7 billion in December 2023 has expanded Danaher's Life Sciences segment, contributing to a 2% revenue boost in 2024 [3] Shareholder Returns - Danaher is committed to rewarding shareholders, having paid out dividends of $768 million in 2024 and $821 million in 2023, with an 18.5% dividend hike to 32 cents per share announced in February 2025 [4] Segment Challenges - The Life Sciences segment faced a 2% decline in core revenues year over year in 2024 due to sluggish demand in pharma and biotech markets in China, impacting sales in mass spectrometry, flow cytometry, lab automation, and microscopy [5] - The Biotechnology segment also showed weakness, with core revenues declining by 4.5% year over year in 2024 due to sluggish demand in discovery and medical businesses [6] Financial Concerns - Danaher reported a long-term debt of $15.5 billion at the end of Q4 2024, with current liabilities of $6.8 billion exceeding cash equivalents of $2.1 billion, and high interest expenses of $278 million in 2024 [7] Stock Performance - Over the past year, Danaher's stock has declined by 19%, compared to a 16% decrease in the industry [8]